Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. The company's lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Market Cap	$999.60M	P/E Ratio	N/A
52W High	$11.46	52W Low	$1.07
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	N/A	52W Position	24.8%
Overall Score	37	Value Score	45
Quality Score	26	Technical Score	40

EPS Current Est	$-0.68	EPS Next Est	$-0.56
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RZLT	$3.65	+2.53%	1.34M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RZLT	$3.65	+2.5%	1.34M
3
4
5
6

RZLT

RZLT

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Rezolute Inc. Data in Excel

Get Rezolute Inc. Data in Excel